Mark Leschly, our Chairman, has served as a member of our board since 2002. Since July 1999, Mr. Leschly has been a Managing Partner with Rho Capital Partners, an investment and venture capital management company. Previously, Mr. Leschly was an Associate and then a General Partner of HealthCare Ventures, a venture capital management company, from 1994 through 1999. Mr. Leschly received an A.B. from Harvard University and an M.B.A. from Stanford Graduate School of Business. In addition to being a director of Verenium Corporation, NitroMed, Inc., Senomyx Inc. and Tercica, Inc., Mr. Leschly is on the board of a number of private companies.

Stephen J. Benkovic, Ph.D., one of our co-founders, has served as a member of our board since its inception in 2000. He is also the co-chair of our scientific advisory board. Dr. Benkovic is the Evan Pugh Professor and Eberly Chair in Chemistry at the Pennsylvania State University. He received a B.S. and an A.B. from Lehigh University, and a Ph.D. in organic chemistry from Cornell University. He became Full Professor at Pennsylvania State University in 1970, Evan Pugh Professor of Chemistry in 1977, and University Professor, Eberly Chair in Chemistry, in 1986. Dr. Benkovic has received a number of awards and fellowships including the Alfred P. Sloan Fellowship, NIH Career Development Award, Guggenheim Fellowship, Pfizer Award in Enzyme Chemistry, Arthur C. Cope Scholar Award, Gowland Hopkins Award, Alfred Bader Award and Repligen Award for Chemistry of Biological Processes. He is a member of the American Academy of Arts and Sciences, the National Academy of Science, the Institute of Medicine and the American Philosophical Society.

Paul Cleveland, has served as a member of our board since September 2007. Mr. Cleveland has served as the Executive Vice President, Corporate Development and Chief Financial Officer for Affymax since January 2006. From April 2004 to December 2005, he served as a managing director at Integrated Finance, Ltd., an investment bank. From September 1996 to April 2003, he served as a managing director at J.P. Morgan Chase and Co. (and a predecessor firm, Hambrecht & Quist), an investment bank. From January 1993 to September 1996, he was a partner at Cooley Godward LLP, a law firm. From December 1988 to December 1992, he was a corporate attorney at Sidley Austin LLP, a law firm, and from September 1981 to November 1988, he was a corporate attorney at Davis Polk & Wardwell, a law firm. Mr. Cleveland holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.

Anders D. Hove, M.D., has served as a member of our board since 2005. Dr. Hove is a general partner of Venrock Associates, a venture capital firm, which he joined in January 2004. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company. Dr. Hove is a member of the boards of directors of Trubion Pharmaceuticals, and a number of privately-held companies. He received an M.Sc. from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from the Institut Européen d'Administration des Affaires, or INSEAD.

Paul H. Klingenstein has served as a member of our board since 2002. He is the managing partner of Aberdare Ventures, a venture capital firm which he founded in 1999. He has been a venture capital investor for most of his professional career. After beginning at Warburg, Pincus, a private equity fund, in the early 1980s, Mr. Klingenstein joined Accel Partners, a venture capital fund in 1986 and helped, through the next decade, to build a leading venture capital firm. Mr. Klingenstein is currently a director of several private companies. He received an A.B. from Harvard University and an M.B.A. from the Stanford Graduate School of Business.

Richard J. Markham has served as a member of our board since 2005. In November 2004, Mr. Markham joined Care Capital, a life sciences venture capital firm, as one of the firms' partners. From May 2002 to August 2004, Mr. Markham was the Vice Chairman of the management board and Chief Operating Officer of Aventis SA, a pharmaceutical company. From December 1999 to May 2002, he was the Chief Executive Officer of Aventis Pharma AG, a pharmaceutical company. Previously he was the Chief Executive Officer of Hoechst Marion Roussel, a pharmaceutical company, the President and Chief Operating Officer of Marion Merrell Dow, a pharmaceutical company, and a member of its board of directors. From 1973 to 1993 Mr. Markham was associated with Merck & Co., a pharmaceutical company, culminating in his position as President and Chief Operating Officer. Mr. Markham is currently a director of Acura Pharmaceuticals. Mr. Markham received a B.S. in Pharmacy and Pharmacal Sciences from Purdue University.

See Management.

Lucy Shapiro, Ph.D., one of our co-founders, has served as a member of our board since our inception in 2000. She is also the co-chair of our scientific advisory board. Dr. Shapiro, the Virginia and D.K. Ludwig Professor of Cancer Research and Director of the Beckman Center in the School of Medicine at Stanford University, has been at Stanford University since 1989. Dr. Shapiro is a Fellow of the American Association for the Advancement of Sciences and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. She was elected to the American Philosophical Society and received the Selman Waksman Award from the National Academy of Sciences in 2005. She was a non-executive director of GlaxoSmithKline from 2001 to 2006. She received a B.S. from Brooklyn College and a Ph.D. in molecular biology from the Albert Einstein School of Medicine.